Objectives The primary aim was to assess whether the use of an isoflavone extract containing 40 mg or 160 total isoflavones affects frequency menopausal flushes and other symptoms. secondary aims were assessments possible effects on menopause symptom scores biological measures estrogen activity.Methods A randomized, double-blind, placebo-controlled prospective trial 37 postmenopausal women with symptoms deficiency performed over a 12-week period. randomized three treatment groups: placebo,...

To estimate the risk of recurrence breast cancer associated with use topical vaginal estrogen therapy in management atrophy women previously treated for cancer.The study group comprised 1472 histologically confirmed cancer. In 69 these subjects (4.7%) their only bothersome menopausal problems were symptoms. women, poorly absorbed cream or tablets used. The response patients was compared that rest database. A Cox regression analysis performed using sex hormone usage after diagnosis as a...

Abstract Objective: To investigate the effect of a ginger extract (EV.EXT35) on symptoms morning sickness. Design: Double‐blind randomised placebo‐controlled trial. Setting: A tertiary metropolitan teaching hospital, March 1999–November 1999. Participants: The participants included 120 women less than 20 weeks pregnant, who had experienced sickness daily for at least week and no relief through dietary changes. Intervention: Random allocation 125 mg (EV.EXT35; equivalent to 1.5 g dried...

Our objective was to examine the effect on all-cause mortality and tumor recurrence rate of combined continuous estrogen-progestin therapy given symptomatic menopausal women with a personal history breast cancer. We performed nested case-control study in cohort The entire database comprised 901 surgically confirmed cancer attending one three teaching hospitals south-eastern Sydney, Australia. Ninety had taken estrogen for relief severe symptoms after their diagnosis treatment Most were using...

Objectives: To assess the acceptability of delivery an isoflavone supplementation in form a powdered drink, and whether dietary isoflavones this manner decreased incidence menopausal flushes. The secondary aims included assessment other symptoms or parameters estrogen deficiency responses to isoflavones. Methods: A randomized, double-blind, placebo-controlled, parallel-group trial comprising 24 postmenopausal women with was performed over 12-week period. were randomized receive beverage...

SUMMARY Fourteen ovulatory patients undergoing diagnostic laparoscopy had at least two samples of clear follicular fluid (FF) collected in the late phase. The cohort concentrations Insulin‐like Growth Factor‐1 (IGF1) were significantly correlated with serum IGF1 and dominant follicles contained higher oestradiol (E2) than their cohorts. After LH surge, a further significant increase FF‐IGF1 occurred. FF‐(log)E2 was both FF volume. Nine women polycystic ovary syndrome (PCOS) one patient...

Purpose The purpose of this paper is to explore the psychosocial experiences people living with dementia using a perceptual control theory (PCT) perspective. Design/methodology/approach Conceptual paper. Findings suggests that may their perceptions by four modes control: control, automatic, passive observation and imagination. Research limitations/implications highlights how perceived sense “too little” or much” can create psychological emotional distress, as seek respond changing contextual...

Objective To evaluate menopausal symptoms and quality of life in middle-aged women.Study design Hospital-based, cross-sectional study.Methods A survey was conducted among 270 women aged 45–65 years who attended the gynecological menopause clinic, Songklanagarind Hospital. We used MENQOL questionnaire as instrument.Results The average age at postmenopausal 48.7 (range 40–57 years). prevalences classical – hot flushes, night sweats, vaginal dryness were 36.8%, 20.8 55.3%, respectively. three...

Aim To investigate the menopausal experience of Arabic women living in Sydney and to explore relationship between psychosomatic symptoms various sociodemographic factors.Method A cross-sectional survey was conducted among 197 aged 45–65 years. The Menopause-specific Quality Life (MENQOL) questionnaire used collect information on characteristics symptoms.Results median age at menopause present study 49 years (mean ± standard deviation, 47.9 5.0 years). Out 29 symptoms, most frequent symptom...

Objectives To assess the safety and efficacy of 10 mg topical testosterone therapy daily (2 cm Andro-Feme® cream) as a treatment for low sexual desire in postmenopausal hysterectomized women who were already on transdermal estrogen.Methods A double-blind, randomized, placebo-controlled, cross-over study (each period being 3 months' duration) was performed research center tertiary referral women's hospital. Thirty-six menopausal healthy recruited had undergone hysterectomy, not depressed,...

OBJECTIVE To compare the effect of a Serenoa repens extract with placebo for symptoms benign prostatic hyperplasia (BPH). PATIENTS AND METHODS In double‐blind placebo‐controlled randomized trial between January 1999 and March 2000, 100 men BPH, aged < 80 years, maximum urinary flow rate 5–15 mL/s voiding volume 150 mL, were randomly equally allocated to 320 mg S. or (paraffin oil). The main outcome measures International Prostate Symptom Score (IPSS), peak rate, Rosen Index Erectile...

Objective To determine whether transdermal progesterone cream has any effect on vasomotor symptoms, mood, sexual response, cardiovascular lipid levels, or bone mineral metabolic markers. Design A parallel, double-blind, randomized, placebo-controlled trial comparing the of a containing (32 mg daily) with placebo cream. Eighty postmenopausal women in Menopause Centre at Royal Hospital for Women, Sydney, were randomly allocated to receive either placebo. They evaluated using Greene Climacteric...

SUMMARY Thirty‐three samples of follicular fluid (FF) were collected from 14 patients with the polycystic ovary (PCO) syndrome and matched for FF‐volume small follicles subjects normal ovaries. The median (range) FF concentration insulin‐like growth factor I (IGF1) in group PCO, 0.42 (0.13‐1.20) U/ml was significantly higher than that controls, 0.33 (0.04‐0.59) U/ml. All tested had < 1 ng/ml FF‐epidermal (EGF) transforming factor‐alpha (TGF‐α). PCO (PCOS) similar FF‐testosterone (T)...